Global Psychiatry Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

DUBLIN, Sept. 23, 2021 /PRNewswire/ -- Gain comprehensive access to over 780 psychiatry deal records from this report "Global Psychiatry Partnering 2014-2021: Deal trends, players and financials" that has been added to ResearchAndMarkets.com's offering.

Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

• Trends in Psychiatry partnering deals
• Financial deal terms for headline, upfront and royalty by stage of development
• Psychiatry partnering agreement structure
• Psychiatry partnering contract documents
• Top Psychiatry deals by value
• Most active Psychiatry dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.

The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Psychiatry dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Psychiatry dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Psychiatry deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Psychiatry deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Psychiatry partnering deals by specific Psychiatry target announced since 2014. The chapter is organized by specific Psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Psychiatry partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Psychiatry partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.

Report scope

Global Psychiatry Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Psychiatry trends and structure of deals entered into by leading companies worldwide.

Global Psychiatry Partnering 2014 to 2021 includes:

• Trends in Psychiatry dealmaking in the biopharma industry since 2014
• Analysis of Psychiatry deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Psychiatry deal contract documents
• Comprehensive access to over 780 Psychiatry deal records
• The leading Psychiatry deals by value since 2014
• Most active Psychiatry dealmakers since 2014

The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.

In Global Psychiatry Partnering 2014 to 2021, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Psychiatry Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 780 psychiatry deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are the sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Global Psychiatry Partnering 2014 to 2021 provides the reader with the following key benefits:

• In-depth understanding of Psychiatry deal trends since 2014
• Access Psychiatry deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between Psychiatry partner companies
• Comprehensive access to over 780 links to actual Psychiatry deals entered into by the world's biopharma companies
• Indepth review of Psychiatry deals entered into by the top 25 most active dealmakers
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner Psychiatry opportunities
• Uncover companies actively partnering Psychiatry opportunities

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Psychiatry dealmaking
2.1. Introduction
2.2. Psychiatry partnering over the years
2.3. Psychiatry partnering by deal type
2.4. Psychiatry partnering by industry sector
2.5. Psychiatry partnering by stage of development
2.6. Psychiatry partnering by technology type
2.7. Psychiatry partnering by therapeutic indication

Chapter 3 -Financial deal terms for Psychiatry partnering
3.1. Introduction
3.2. Disclosed financials terms for Psychiatry partnering
3.3. Psychiatry partnering headline values
3.4. Psychiatry deal upfront payments
3.5. Psychiatry deal milestone payments
3.6. Psychiatry royalty rates

Chapter 4 - Leading Psychiatry deals and dealmakers
4.1. Introduction
4.2. Most active in Psychiatry partnering
4.3. List of most active dealmakers in Psychiatry
4.4. Top Psychiatry deals by value

Chapter 5 - Psychiatry contract document directory
5.1. Introduction
5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Psychiatry therapeutic target

Appendices

Companies Mentioned

• 3B Medical
• 3PrimeDx
• 23andMe
• Abbvie
• AbCellera
• Academic Drug Discovery Consortium
• Accera Pharmaceuticals
• Acer Therapeutics
• AC Immune
• Actelion
• AcuraStem
• AdAlta
• Adamas Pharmaceuticals
• Adare Pharmaceuticals
• Addex Therapeutics
• Adimab
• Admera Health
• Advanced Cooling Therapy
• Advocate Health Care
• ADx Healthcare
• Aelan Cell Technologies
• Aequus Pharmaceuticals
• Aerial BioPharma
• Affymetrix
• Agena Bioscience
• AgeneBio
• Agilis Biotherapeutics
• AiCure
• Aiforia Technologies
• Air Force General Hospital
• AIT Laboratories
• Akili Interactive Labs
• Alector
• Alexion Pharmaceuticals
• Alexza Pharmaceuticals
• Alkahest
• Alkermes
• Allen Institute for Brain Science
• Allergan
• Allergan (name changed from Actavis)
• Allied Corp
• Alpha Cognition
• Alphaeon
• ALS Association
• Alvogen
• Alzamend Neuro
• Alzeca Biosciences
• Alzecure Foundation
• Alzheimer's Association
• Alzheimer's Drug Discovery Foundation
• Alzheimer's Foundation of America
• Alzheimer's Research UK
• Alzheimer Society Research
• Alzheimers Research UK
• AlzProtect
• Alzyn
• Amarantus BioSciences
• Ambry Genetics
• AmCad BioMed
• American Diabetes Association
• American Heart/Stroke Association
• American Sleep Apnea Association
• American Well
• Amerigen Pharmaceuticals
• Amgen
• Amherst Pharmaceuticals
• Amneal Pharmaceuticals
• Amorsa Therapeutics
• Amydis Diagnostics
• Analytical Testing Laboratory
• Anavex Life Sciences
• Andor Pharmaceuticals
• ANI Pharmaceuticals
• Annovis Bio
• Apnea Sciences
• Apotex
• APRINOIA Therapeutics
• Aptinyx
• Aquinnah Pharmaceuticals
• Araclon Biotech
• ARCH Personalized Medicine Initiative
• Arena Pharmaceuticals
• Arizona State University
• Armor
• Artelo Biosciences
• Association for Frontotemporal Degeneration
• Assurex Health
• Assuta Medical Centers
• Astellas Pharma
• Astex Pharmaceuticals
• AstraZeneca
• AstronauTx
• ATAI Life Sciences
• Aurora Cannabis
• Australian Imaging
• Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
• Autifony Therapeutics
• Autism Learning Partners
• Autism Speaks
• Avicanna
• AXIM Biotechnologies
• AxoSim
• Axsome Therapeutics
• Axxam
• Bachmann-Strauss Dystonia & Parkinson Foundation
• Bain Capital
• Banner Alzheimer's Institute
• Banner Health
• Bayer
• Baylor College
• Baylor College of Medicine
• BC Neuroimmunology
• BDD Pharma
• BehaVR
• Beijing Double-Crane Pharmaceutical
• Beijing Leadman Biochemistry
• Berg
• Best Choice
• Bestmed
• Beurer
• Biametrics
• Bicycle Therapeutics
• Bill and Melinda Gates Foundation
• BioArctic Neuroscience
• biOasis Technologies
• Biocodex
• Biodextris
• Biogen
• Biohaven Pharmaceutical Holding
• Biomedical Catalyst Fund (UK)
• BioMed X Innovation Center
• Bionomics
• Biopharmaceuticals Australia
• Bioprojet
• BioTie Therapies
• Blackfynn
• BlackThorn Therapeutics
• Blake Insomnia Therapeutics
• Blanchette Rockefeller Neurosciences Institute
• Blum Center for Health
• BMC Medical
• Boehringer Ingelheim
• Boston Scientific
• Boston University
• Boston University School of Medicine
• Bpifrance
• Bracket
• Brain & Behavior Research Foundation
• Brain Balance Achievement Centers
• Brain Biomarker Solutions in Gothenburg
• Brainsway
• Breakthrough Diagnostics
• Breathe ECig
• Breckenbridge Pharmaceutical
• Brigham and Women's Hospital
• BrightFocus Foundation
• Bristol-Myers Squibb
• Broad Institute
• Brown University
• Buck Institute for Age Research
• BullFrog AI
• C2N Diagnostics
• C4 Therapeutics
• C4X Discovery
• Cadent
• Calico
• Camargo Pharmaceutical Services
• Cambridge Brain Sciences
• Cambridge Cognition
• Camino Pharma
• Canadian Institutes of Health Research
• CannRx Technology
• Cannvalate
• Caprion Biosciences
• Caputron Medical
• Cardiff University
• CareCentrix
• CareFusion
• Carna BioSciences
• CarThera
• Case Western Reserve University
• Casma Therapeutics
• Cassava Sciences
• Catalent
• Cato Research
• CavoGene LifeSciences
• CB2 Insights
• CB Therapeutics
• CEITEC
• Celgene
• Cellectricon
• Cellular Dynamics International
• Centene
• Center for iPS Cells Research and Application
• Cerebain Biotech
• Cerebral Therapeutics
• Cerecor
• Cerevel Therapeutics
• Certainty Health
• Certara
• Cerveau Technologies
• Cervel Neurotech
• Chaperone Technologies
• Charles River Laboratories
• Chattanooga Center for Neurologic Research
• ChemDiv
• Children's Hospital Boston
• Children's Minnesota
• Chronos Therapeutics
• Chugai Pharma Marketing
• Cingulate Therapeutics (CTx)
• Cipla Medpro
• Circuit Therapeutics
• City of Hope
• Clalit Health Services
• Cleveland Clinic
• Click Therapeutics
• Clinical Imaging Research Centre
• Cloud Pharmaceuticals
• CluePoints
• Cogito
• Cognetivity Neurosciences
• Cognition Kit
• Cognition Therapeutics
• Cognoa
• CogState
• Cohen Veterans Bioscience
• Columbia University
• Complement Pharma
• Compumedics
• Concept Life Sciences
• Confo Therapeutics
• Connecticut Children's Medical Center
• Context Therapeutics
• Coriell Institute for Medical Research
• Corium International
• Cortex Pharmaceuticals
• Cortexyme
• Cortice Biosciences
• Corvida Medical
• COTA
• Courtagen Life Sciences
• CRC Health
• CRISPR Therapeutics
• Crossbeta Biosciences
• CryoPort
• CTD Holdings
• Cure Alzheimer's Fund
• CURE Pharmaceutical
• Cybin
• Cyclica
• Cyclo Therapeutics
• Cypralis
• Cyrenaic Pharmaceuticals
• Cytox
• Dacadoo
• Daiichi Sankyo
• Dainippon Sumitomo Pharma
• Dalhousie University
• Deep Cube
• Defense Advanced Research Projects Agency
• Dehaier Medical Systems
• Delivering Scientific Innovation for Autism (DELSIA)
• Dementia Consortium
• Dementia Discovery Fund
• Denali Therapeutics
• Dengg Medizintechnik
• Denovo Biopharma
• Department of Defense
• Department of Health and Human Services
• Department of Veterans Affairs
• DiamiR
• Dicerna Pharmaceuticals
• DKSH
• Drukier Institute for Children's Health
• DSG
• DuChemBio
• Duke University
• Duke University Medical Center
• Durect
• DyNAbind
• Dystonia Europe
• Dystonia Medical Research Foundation
• DZNE German Center for Neurodegenerative Diseases
• E3x Bio
• Eagle Pharmaceuticals
• EarlySense
• Early Signal Foundation
• Ecole Polytechnique Federale de Lausanne
• Edith Cowan University (ECU)
• eemagine
• Egenix
• Ehave
• Eisai
• Electrical Geodesics
• Eli Lilly
• Elite Pharmaceuticals
• Ellison Medical Foundation
• Emerge Health
• Emory University
• Endo International
• Endotherm
• Endotronix
• Enigma Biomedical
• Entheogenix Biosciences
• Ergomed
• ERP Biomarker Qualification Consortium
• Essex Bio-Technology
• Eureka Eurostars
• Eurofarma
• European Parkinson's Disease Association
• European Prevention of Alzheimer's dementia Initiative (EPAD)
• Evecxia
• EverInsight Therapeutics
• Evero Health
• Evidation Health
• Evolent Health
• Evotec
• Exeltis
• Expesicor
• Exploragen
• ExScientia
• Ez Sleep Technologies
• Fabre Kramer Pharmaceuticals
• Feinstein Institute for Medical Research
• Field
• Florey Institute of Neuroscience and Mental Heath
• Florida Atlantic University Research
• Flowonix
• Fondazione Telethon
• Food and Drug Administration (FDA)
• Forest Pharmaceuticals
• FORMA Therapeutics
• Foundation for the National Institutes of Health (FNIH)
• Fudan University
• Fujirebio Diagnostics
• FusionHealth
• Fuzionaire Diagnostics
• GABA Therapeutics
• Gaia
• Galen
• GCA Therapeutics
• Genco Sciences
• Genentech
• Geneva University Hospitals
• Genoma
• Genomind
• Georgetown University
• GHR Foundation
• Gilead Sciences
• Ginkgo BioWorks
• GlaxoSmithKline
• GL Brands
• GliaCure
• Global Alliance for Innovation in Neuroscience
• Global Alzheimer's Platform (GAP)
• Gnome Diagnostics
• Gnosis Bioresearch
• Golden Meditech
• Gour Medical
• Green Valley Pharmaceutical
• Grifols
• Grupo Ferrer
• Gurnet Point Capital
• Hackensack Meridian Health
• Hainan Sinotau Pharmaceutical
• Hannover Medical School
• Happify Health
• Harmony Biosciences
• Harvard Medical School
• Harvard University
• Health Connexions
• Healthsense
• Hebrew SeniorLife
• Hebrew University of Jerusalem
• HEI Life Sciences
• Helius Medical Technologies
• Helix
• Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center
• Helsinn Healthcare
• HemispheRx Biopharma
• Hertie Foundation
• HLS Therapeutics
• HMNC Brain Health
• Hollister Biosciences
• Holobiome
• Hong Kong Baptist University
• Horizon Healthcare Services
• Human Metabolome Technologies
• Hummingbird Diagnostics
• I-mab
• iBIO Institute's PROPEL Center
• IBM
• Icagen
• Icahn School of Medicine at Mount Sinai
• ICAN
• Icon
• Idorsia
• Ildong Pharmaceutical
• ILiAD Biotechnologies
• Imanova
• ImmunoBrain Checkpoint
• Impax Laboratories
• Impel NeuroPharma
• Imperial College London
• Impression Healthcare
• India Globalization Capital
• Indivior
• Inexia
• Initiator Pharma
• Innovate UK
• Innovative Medicines Initiative (IMI)
• Inoviem Scientific
• Inovio Pharmaceuticals
• In Silico Biosciences
• Institute for Functional Medicine
• IntegraGen
• IntelGenx
• IntelliCell BioSciences
• Intellipharmaceutics
• InteRNA Technologies
• International Flavors and Fragrances
• Inventia Healthcare
• inVentiv Health
• inviCRO
• Ionis Pharmaceuticals
• Ironshore Pharmaceuticals
• ISIS Innovation
• IsoPlexis
• Itamar Medical
• IXICO
• Janssen Biotech
• Janssen Korea
• Janssen Pharmaceuticals
• Janssen Pharmaceutica NV
• Janssen Research & Development
• Japan Tobacco
• Jazz Pharmaceuticals
• Jewel-Osco
• Jiangsu NHWA Pharmaceutical
• John Ballard
• Johns Hopkins University
• Johnson & Johnson
• And Many More Companies!

For more information about this report visit https://www.researchandmarkets.com/r/gc87md

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com